Evidence map›Paper›PMID 37514112›Full record

ArticlePharmaceutics2023

EHO-85, Novel Amorphous Antioxidant Hydrogel, Containing

José Verdú-Soriano, Marisol de Cristino-Espinar, Silvia Luna-Morales, Caridad Dios-Guerra, Antonio Casado-Díaz, José Manuel Quesada-Gómez, Gabriel Dorado, Miriam Berenguer-Pérez, Susana Vílchez, Jordi Esquena and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

José Verdú-SorianoDepartment of Community Nursing, Preventive Medicine, Public Health and History of Science, Faculty of Health Sciences, University of Alicante, 03690 Alicante, Spain.ORCID 0000-0002-8307-7323
Marisol de Cristino-EspinarPharmacy Department, Reina Sofia University Hospital, 14004 Córdoba, Spain.
Silvia Luna-MoralesMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofía University Hospital, University of Córdoba, 14004 Córdoba, Spain.
Caridad Dios-GuerraMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofía University Hospital, University of Córdoba, 14004 Córdoba, Spain.
Antonio Casado-DíazMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofía University Hospital, University of Córdoba, 14004 Córdoba, Spain.ORCID 0000-0002-8520-8278
José Manuel Quesada-GómezMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofía University Hospital, University of Córdoba, 14004 Córdoba, Spain.
Gabriel DoradoConsortium for Biomedical Research in Frailty & Healthy Ageing (CIBERFES), Institute of Health Carlos III, 28029 Madrid, Spain.
Miriam Berenguer-PérezDepartment of Community Nursing, Preventive Medicine, Public Health and History of Science, Faculty of Health Sciences, University of Alicante, 03690 Alicante, Spain.
Susana VílchezInstitute of Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Científicas (IQAC-CSIC), 08034 Barcelona, Spain.
Jordi EsquenaInstitute of Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Científicas (IQAC-CSIC), 08034 Barcelona, Spain.ORCID 0000-0002-9188-5259
Leocadio Rodríguez-MañasConsortium for Biomedical Research in Frailty & Healthy Ageing (CIBERFES), Institute of Health Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-6551-1333
José Luis Lázaro-MartínezDiabetic Foot Unit, University Podiatry Clinic, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0001-6110-0265
Instituto de Salud Carlos III · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ESConsejo Superior de Investigaciones Científicas · ESUniversity of Alicante · ESUniversidad Complutense de Madrid · ES

Funding

Ministry of Economy and Competitiveness INNCORPORA-TU-2011-1886 subprogramNoventure, Ferrer company group 01QUESPER R&D 01Regional Government of Andalusia Reinforcement of Research Activity in the Clinical Management Units of the Andalusian Health Service
6 · The paper itself

Abstract

Many advanced wound healing dressings exist, but there is little high-quality evidence to support them. To determine the performance of a novel amorphous hydrogel (EHO-85) in relation to its application, we compared its rheological properties with those of other standard hydrogels (SH), and we assessed the induction of acceleration of the early stages of wound healing as a secondary objective of a prospective, multicenter, randomized, observer-blinded, controlled trial. The patients were recruited if they had pressure, venous, or diabetic foot ulcers and were treated with EHO-85 (

Indexed as

amorphous hydrogeldiabetic foot ulcerEHO-85pressure ulcerrandomized active-controlled trialvenous leg ulcer

Identifiers

PMID37514112
PMCPMC10383111
OpenAlexW4383912408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.